Correlation of PTX3,VEGF and Coagulation Fibrinolysis Imbalance in Type 2 Diabetic Microangiopathopathy

Yu Jiahui; Gu Feng; Ma Shiqi

doi:10.3969/j.issn.1004-5775.2025.02.021

Abstract：Objective:In order to explore the correlation between the changes of serum PTX3 and VEGF expression and coagulation-fibrinolysis imbalance in type 2 diabetic patients with microangiopathy.Methods:120 patients with type 2 diabetes admitted to the hospital from January 2020 to January 2023 were selected according to the microangiopathy,and divided into control group(n=60)and observation group(n=60).The control group had microangiopathy,and the observation group had microangiopathy.PTX3,VEGF and coagulation-fibrinolysis indexes of patients were detected,and the correlation between PTX3,VEGF levels and coagulation-fibrinolysis indexes was analyzed.The correlation between PTX3,VEGF,coagulation-fibrinolysis indexes and type 2 diabetic microangiopathy was analyzed.Results:Compared with the control group,the levels of serum PTX3 and VEGF in the observation group were significantly increased(t=2.826,P＜0.05).The levels of fibringen(FIB)and D-dimer(DD)in observation group were significantly higher than those in control group,while the levels of prothrombin time(PT),thrombin time(APTT)and thrombin time(TT)in observation group were significantly lower than those in control group,with statistically significant difference(t=4.449,7.519,2.267,3.177,5.035;P＜0.05).PTX3 and VEGF were positively correlated with coagulation function(r=0.485,0.421,P＜0.05),and negatively correlated with fibrinolytic function(r=-0.212,-0.314,P＜0.05).PTX3 and VEGF were independent risk factors for microangiopaopathy in type 2 diabetes mellitus(OR=1.274,1.473;P＜0.05).Conclusion:The expression levels of PTX3 and VEGF are up-regulated in type 2 diabetic microangiopathy patients,the prothrombin time is shortened,the coagulation function is enhanced,and the fibrinolytic ability is weakened.PTX3 and VEGF are correlated with coagulation function,and are independent risk factors for microangiopathy in patients with type 2 diabetes mellitus.